Abbott's acquisition of two companies creates new opportunities for medical device business

Abbott recently acquired two companies for up to $710 million, further expanding the company's medical device business, expanding the product portfolio of vascular stents and treatment options in the ophthalmic field The acquired Idev technologies is a developer of innovative stent technology, while optimedica is a leader in ophthalmic laser technology These two acquisitions will further promote Abbott's position in the cardiovascular and ophthalmic medical products market   Idev technologies is a private company focused on research and development, mainly providing new generation medical instruments for interventional radiotherapy doctors, cardiovascular surgeons and cardiologists According to the terms of the agreement, Abbott contributed US $310 million to acquire Idev technologies The acquisition has strengthened Abbott's cardiovascular business, expanded its global product portfolio, and enabled the company to obtain the super Veritas self expanding nitinol alloy stent system with European CE (conformaeuropen) certification mark, which is used to treat the blockage of blood vessels caused by peripheral arterial disease (PAD) The stent can open the blocked vessels and prevent re blockage   Super Veritas has patented technology of thread interweaving, which aims to promote the blood flow of the parts to be treated according to the bionic principle (trying to imitate the natural activity of the human body), and has certain strength and softness These patented technologies are particularly important in the treatment of vascular blockages in areas where rapid and frequent activity is required during daily activities such as walking, sitting, and standing, such as thighs and knees   Chuck Foltz, senior vice president of cardiovascular department of Abbott, said: "the acquisition of Idev technologies will expand and make up the product portfolio of guide wire, balloon catheter and stent of Abbott's existing peripheral disease treatment technology, making it one of the most comprehensive and competitive product portfolio in the industry This technology has the potential to have a significant impact on the treatment of patients suffering from peripheral arterial disease, which is currently a growing global concern "   Up to 27 million people in Europe and North America are suffering from peripheral artery disease In addition, the increasing prevalence of the disease is likely to increase the economic burden on the health care system, so timely and effective treatment becomes very important   About 22 million cataract operations are performed every year in the world At present, most cataract operations are performed by hand Surgeons open the eyes manually The application of laser technology in cataract surgery is relatively cutting-edge Through the acquisition of optimedica, an ophthalmic laser equipment company, of up to $400 million, Abbott is now able to compete in the fast-growing market of laser-assisted cataract surgery   The "catalys precision laser system" approved by optimedica in the United States and Europe will be the next generation laser platform, which can replace the technical requirements of manual operation in cataract surgery and is a more predictive computer-guided femtosecond laser technology   Murthy simhambhatla, senior vice president of Abbott's Medical Optics department, said: "the acquisition of optimedica will provide Abbott with a good opportunity to enter the rapidly developing field of laser-assisted cataract surgery Catalys precision laser system will provide doctors with the most advanced fully automatic surgical options to help patients get rid of cataract."   Abbott is a global leader in the field of cataract intraocular lens Its Tecnis series products include single focus, multi focus and complex curved intraocular lens At present, the sales volume of cataract related products on sale accounts for 60% of the total sales volume of Abbott's ophthalmic products.